Endotoxin elimination in sepsis: physiology and therapeutic application
- 635 Downloads
The present review summarizes key papers on the elimination of endotoxin in human.
Lipopolysaccharides (LPS) are extremely strong stimulators of inflammatory reactions, act at very low concentrations, and are involved in the pathogenesis of sepsis and septic shock. Elimination of LPS is vital; therefore, therapeutic detoxification of LPS may offer new perspectives. Multiple mechanisms eliminate LPS in human comprising molecules that bind LPS and prevent it from signaling, enzymes that degrade and detoxify LPS, processes that inactivate LPS following uptake into the reticulo-endothelial system, and mechanisms of adaptation that modify target cells responding to LPS. These mechanisms are powerful and detoxification capacity adapts as required. Results of therapeutic interventions aiming at the removal of LPS by medication (immunoglobulins) or extracorporeal means are controversial. At least in part, animal experiments revealed increased survival. Human trials confirmed the positive effects on parameters of secondary importance, but not on morbidity or survival which was attributed to the heterogeneity of patients suffering from consequences of severe infectious diseases and sepsis.
The hypothesis of LPS-driven inflammatory processes remains very attractive. However, few therapeutic yet immature options have been developed to date.
KeywordsLipopolysaccharide Elimination Detoxification Degradation Adsorber
No funding was received for doing this overview. Klaus Buttenschoen, Peter Radermacher, and Hendrik Bracht are authors of the publication Eur Surg Res (2009) 43:53–60, “Efficacy of an Extracorporeal Endotoxin Adsorber System during Hyperdynamic Porcine Endotoxemia”. This study was supported by a research grant of Fresenius Company, Germany.
- 7.Gazzano-Santoro H, Meszaros K, Birr C, Carroll SF, Theofan G, Horwitz AH, Lim E, Aberle S, Kasler H, Parent JB (1994) Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and Gram-negative bacteria. Infect Immun 62:1185–1191PubMedGoogle Scholar
- 33.Taniguchi T, Hirai F, Takemoto Y, Tsuda K, Yamamoto K, Inaba H, Sakurai H, Furuyoshi S, Tani N (2006) A novel adsorbent of circulating bacterial toxins and cytokines: the effect of direct hemoperfusion with CTR column for the treatment of experimental endotoxemia. Crit Care Med 34:800–806PubMedGoogle Scholar
- 35.Kojika M, Sato N, Yaegashi Y, Suzuki Y, Suzuki K, Nakae H, Endo S (2006) Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 10:12–18CrossRefPubMedGoogle Scholar
- 41.Nakamura T, Fujiwara N, Sato E, Kawagoe Y, Ueda Y, Yamada S, Koide H (2009) Effect of polymyxin B-immobilized fiber hemoperfusion on serum high mobility group box-1 protein levels and oxidative stress in patients with acute respiratory distress syndrome. ASAIO J 55:395–399CrossRefPubMedGoogle Scholar
- 46.Hurley JC, Levin J (1999) The relevance of endotoxin detection in sepsis. In: Brade H, Opal SM, Vogel SN, Morrison DC (eds) Endotoxin in health and disease. Marcel Dekker, New York, pp 841–854Google Scholar